Antineoplastic Agents, Immunological Concept

Vocabulary Service

MeSH

Overview

subject area of

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies Journal Articles
A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis Journal Articles
Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety? Journal Articles
Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations. Journal Articles
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma Journal Articles
Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world Journal Articles
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial Journal Articles
Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma. Journal Articles
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma Journal Articles
Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review Journal Articles
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer Journal Articles
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis Journal Articles
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221 Journal Articles
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events Journal Articles
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Journal Articles
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Journal Articles
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma Journal Articles
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^* Journal Articles
Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites Journal Articles
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP) Journal Articles
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors Journal Articles
Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review Journal Articles
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer Journal Articles
Immunotherapy in the Elderly Journal Articles
Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses Journal Articles
Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients Journal Articles
Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab Journal Articles
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial Journal Articles
Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use Journal Articles
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013 Journal Articles
Predictors of Immunotherapy-Induced Immune-Related Adverse Events Journal Articles
Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort Journal Articles
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Journal Articles
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors Journal Articles
Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer Journal Articles
Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review Journal Articles
Targeted therapy for metastatic renal cell carcinoma Journal Articles
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma Journal Articles
The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population Journal Articles
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis Journal Articles
Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience. Journal Articles
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Journal Articles